key: cord-0783792-6yof1vw7
authors: Jothimani, Dinesh; Vij, Mukul; Sanglodkar, Uday; Patil, Vaibhav; Sachan, Deepti; Narasimhan, Gomathy; Kaliamoorthy, Ilankumaran; Rela, Mohamed
title: Severe jaundice in a COVID-19 patient-virus or drug?
date: 2021-02-25
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2021.02.006
sha: 8da880bec23b18bbf680724586508772f02a87a0
doc_id: 783792
cord_uid: 6yof1vw7

nan

up and autoantibody profile was negative. There was no history of CAMs or ayurvedic products intake. His RUCAM (Roussel Uclaf causality assessment method) score was +7 indicative of 'probable' drug induced liver injury (DILI). A percutaneous liver biopsy showed largely maintained lobular architecture with prominent centrilobular hepatocanalicular bilirubinostasis, mild lobular activity and hepatocellular ballooning ( Figure 1A-1D) . He was commenced on cholestyramine for pruritus and received a session therapeutic plasma exchange. His clinical symptoms improved with reduction in jaundice.

The cause of liver injury is multi-factorial in COVID-19, and it is difficult to pinpoint the cause of liver injury in COVID-19. 1,2 Considering RUCAM score of +7 and liver histology we suggest that the probable association of dabigatran with the cholestatic injury in this patient after exclusion of other known causes. Mechanism of dabigatran DILI liver injury is unknown, probably an idiosyncratic reaction. Mostly the liver injury hepatocellular but rarely cholestatic pattern observed. 3 In a largest French database analysis of patients with atrial fibrillation, hepatic dysfunction occurred in 2.6% of patients with dabigatran as compared to 3.5% in the warfarin group over a 1-year period. 4 A study of FDA adverse event reporting system on 13,096 patients on dabigatran showed 1.7% hepatotoxicity, with higher female preponderance (75%). 5 

Pathogenesis of Liver Injury in Coronavirus Disease

COVID-19 and the liver

Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis

Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. Sci Rep

Drug Hepatotoxicity: Newer Agents. Clin Liver Dis

Hepatocanalicular bilirubinostasis (marked with arrow) with mild lobular activity (H&E, X150, C). Patchy cellular ballooning